The co-assembly of CD8+ and CD4+T cell epitopes with the designed K/E peptide elicits robust anti-tumor T cell immunity, surpassing that induced by aluminum adjuvant, through selective activation of the MyD88–NF-κB signaling pathway without triggering detectable inflammatory responses [107]. This evidence concerns the gene CD8A and neoplasm.